Metformin targets Clusterin to control lipogenesis and inhibit the growth of bladder cancer cells through SREBP-1c/FASN axis
Open Access
- 1 March 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 6 (1), 1-3
- https://doi.org/10.1038/s41392-021-00493-8
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81874212, 81703008)
This publication has 5 references indexed in Scilit:
- Metformin inhibits pancreatic cancer metastasis caused by SMAD4 deficiency and consequent HNF4G upregulationProtein & Cell, 2021
- Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic OpportunitiesCancers, 2019
- PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III TrialClinical Cancer Research, 2019
- Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinomaCancer Letters, 2017
- High efficacy of intravesical treatment of metformin on bladder cancer in preclinical modelOncotarget, 2016